Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VRTXBearishAnalyst Target Updateanalyst

Medium materiality6/10

Vertex Pharmaceuticals price target raised to $350 from $330 at Baird

Jul 7, 2026, 8:23 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Analyst target changes matter most when the new target creates a material gap versus current price or confirms a recent catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Baird raises Vertex PT to $350 from $330; current price $529.59.

Baird raises VRTX PT to $350; price $529.59.

Key facts

01
Target: $350
02
Posted price: $529.59
03
Analyst firm: Robert W. Baird

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Vertex Pharmaceuticals price target raised to $350 from $330 at Baird

Key facts

Vertex raises upper end of revenue forecast on strong CF drug demand

Vertex to Acquire Crinetics for $10B to Expand Pipeline and Revenue

FDA Expands Vertex Gene Therapy to Children as Young as Two with Blood Disorders

Vertex Pharmaceuticals Surpasses Earnings Expectations with Sales Surge